Last Updated: 02/18/2022
Scion Lab Services, LLC currently offers SARS-CoV-2 testing.
SARS-CoV-2 RNA detection of SARS-CoV-2 is used for individuals who have clinical symptoms of COVID-19 disease or meet the testing criteria established by the CDC.
SARS-CoV-2 IgG antibody test is suggested for individuals who may have had COVID-19 disease and do not have symptoms.
Book Appointment →Scion Genomics* utilizes real time PCR-based technology to evaluate multiple genes for mutations that are known to impact how the body metabolizes certain medications. We provide patient specific information about which medications are the safest and most effective to prescribe.
Includes genes that affect the bodies response to over 44 medications commonly prescribed to treat psychiatric disorders.
Includes multiple genes that affect the bodies response to medications commonly prescribed to treat cardiovascular disease. The cardiac panel also includes testing for an APOE ε2 variant; a risk factor in hyperlipoproteinemia type III and genes that assist in the evaluation of an increased the risk for venous
*Scion Genomics, A Division of Scion Lab Services, LLC
Learn More →LCMS/MS provides identification and quantification of drug metabolites based on characteristic molecular fragmentation patterns and specific retention times of the metabolite molecules. This is particularly useful for physicians and other health care providers to determine an appropriate patient-specific regimen for detoxification protocols. Initial screening does not always identify exactly what drug has been found in urine. Confirmation testing, as a more sensitive analysis, employs different technology than the initial screening method. It is used to confirm the presence of a drug, or further pinpoint which drug made the initial result positive. We are continuously reviewing and modifying our offered Test Menu to ensure that the evolving list of illicit and abused drugs can be tested for and monitored by our customers.
Scion Lab Services utilizes enzyme immunoassay (EIA) technique to detect the presence of 8 drugs and 5 drug classes, as well as to determine urine specimen validity. With the combination of liquid chromatography and mass spectroscopy (LCMS-MS), we are able to uniquely identify over 80 drug analytes in urine, thereby enabling us to confirm initial screen results.
Screens do not always detect the presence of drugs or identify which drug may have triggered a positive result. To confirm the presence of a drug, or further pinpoint which drug made the initial result positive, secondary analysis is performed on the same specimen, using highly sensitive LCMS-MS. This form of confirmation testing aids in ensuring that prescribed medication is being taken appropriately and helps to establish a pattern of use. This is helpful information for patients in pain management programs and essential for patients in drug replacement therapy programs.
We begin by screening the urine specimen for pertinent validity information, such as creatinine levels, pH, specific gravity and general oxidants, each of which aids in detecting whether someone might be attempting to adulterate a drug test by masking, diluting or substituting his or her urine. The screen for drugs then provides positive or negative results, indicating the presence or absence of a drug or class of drugs.
Scion Lab Services provides automated Serum Chemistry Testing that uses colorimetry, turbidimetry, latex agglutination, homogeneous EIA, and Indirect ISE technology. The chemistry testing we provide aids the physicians in providing specialized treatment protocols for patients in conjunction with toxicology and hematology results.
Scion Lab Services provides automated in vitro diagnostic testing of a Complete Blood Count (CBC) and a 3-part automated differential white blood cell count. Physicians and health care providersare able to utilize the results from the CBC and differential to provide a complete treatment protocol along with the Toxicology and Serum Chemistry results on an individualized level.
Scion Lab Services provides testing for Infectious Diseases on our Architect i1000sr instrument utilizing chemiluminescent microparticle immunoassay technology (CMIA), including: Hepatitis B Core IgM and Hepatisis B Surface Antigen, Hepatitis C, Syphilis, and HIV.
Scion Lab Services provides testing for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) using the Cepheid GeneXpert Instrument. The Cepheid GeneXpert CT/NG test is an automated in vitro diagnostic test for qualitative detection and differentiation of DNA from CT and NG. The GeneXpert Instrument Systems automate and integrate sample purification, nucleic acid amplification, and detection of the target sequences in simple or complex samples using real-time PCR and RT-PCR assays.
Scion Lab Services provides testing for diseases of the endocrine system affecting various hormones. Hormones that are specific to male and female patients are tested on our Architect i1000sr instrument using chemiluminescent microparticle immunoassay technology (CMIA).
Scion Lab Services provides testing for monitoring therapy response to individuals who have ovarian and prostate cancer. The Total PSA assay is also useful, in addition to a digital rectal exam in detection of prostate cancer. CA 125 and Total PSA are tested on our Architect i1000sR instrument using chemiluminescent microparticle immunoassay technology (CMIA).